Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 11/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741080 | 0.77 | SCN9A (0.38) | SCN9AABL1 | |
| SCHEMBL16742677 | 0.74 | HPGD (0.36) | CTPS1BRPF1PTGS1PTGS2 | |
| SCHEMBL18066256 | 0.74 | PIK3C3 (0.32) | TDP1PIK3C3 | |
| SCHEMBL21381576 | 0.73 | CTPS1 (0.43) | CTPS1SCN9AABL1MAP4K1TDP1 | |
| SCHEMBL16742629 | 0.73 | BRPF1 (0.42) | CTPS1BRPF1MAP2K4SGK1 | |
| SCHEMBL18065939 | 0.73 | TSHR (0.45) | PIK3C3 | |
| SCHEMBL17803526 | 0.69 | CTPS1 (0.42) | CTPS1SCN9AABL1TDP1BRPF1 | |
| SCHEMBL24369034 | 0.68 | SCN9A (0.50) | CTPS1SCN9ATDP1PTGS1PTGS2 | |
| SCHEMBL16827647 | 0.68 | SCN9A (0.50) | CTPS1SCN9ATDP1PTGS1PTGS2 | |
| SCHEMBL18802292 | 0.68 | ALDH1A1 (0.55) | CTPS1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | claimed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | claimed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | claimed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | claimed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | disclosed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, HTR1B, HTR1A | CTPS1 655/4885SCN9A 2465/4885ABL1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.